NCI's Dr. Robert Wiltrout Named FLC's Lab Director of the Year
NCI’s Dr. Robert H. Wiltrout has won the 2010 Laboratory Director of the Year award from the Federal Laboratory Consortium for Technology Transfer (FLC). This award is presented annually to directors who have made outstanding contributions to supporting technology transfer activities in the laboratory. Because of the competitiveness and prestige of the award, the honor recognizes both the award recipient’s efforts and his or her facility's technology transfer program.
Dr. Wiltrout, director of NCI’s Center for Cancer Research (CCR), also heads the Experimental Therapeutics Section in CCR’s Laboratory of Experimental Immunology. His work there focuses on understanding complex immune interactions in vivo and developing preclinical uses of immunotherapy, alone and in combination with other molecularly targeted strategies, for translation to clinical trials in cancer patients.
Dr. Wiltrout will receive the award April 29 at the FLC national meeting in Albuquerque, NM.
Learn about NCI's Cancer Biobank at caHUB Public Information Meetings
In response to the lack of standardized, high-quality biospecimens for cancer research, NCI plans to develop a national cancer human biobank (caHUB). The aim of caHUB is to modernize the field of biobanking and contribute to medical advances by making high-quality human specimens and data available, as well as analysis, scientific tools, and services to the cancer research and product development communities.
NCI invites you to attend one of two public meetings to learn more about the caHUB planning process and mission, and review the implementation, structure, timeline, and funding process. Meeting dates and locations are:
February 19 from 8:30 a.m.–12:00 noon, ET
Natcher Auditorium, NIH main campus
March 1 from 8:30 a.m.–12:00 noon, PT
University of California, Los Angeles campus
To learn more, register, and view the videocast, please visit the caHUB meeting Web site.
NCI Symposium Will Look at Translational Genomics
On March 4–5, the NCI Center of Excellence in Integrative Cancer Biology and Genomics will host a symposium titled, “Translational Genomics: Looking Back and Moving Forward.” Participants will gather in Natcher Auditorium on the NIH main campus to discuss ways to advance and implement novel technologies, develop clinical and bioinformatic infrastructures, and discuss how best to translate these technologies into clinical practice to improve the health of patients with cancer. Topics will include:
- Critical assessment of translational genomics
- Implementation of novel technologies
- Infrastructure development
World Cancer Day Observed on February 4
To recognize World Cancer Day on February 4, the International Union Against Cancer (UICC) launched “Cancer can be prevented too,” a global campaign to raise public awareness of cancer and how a number of simple steps can significantly reduce the risk of developing cancer:
- Stop tobacco use and avoid exposure to second-hand smoke
- Limit alcohol consumption
- Avoid excessive sun exposure
- Maintain a healthy weight through eating healthily and exercising regularly
- Protect against cancer-causing infections
The 2010 campaign report highlights cancers that can be caused by infectious agents (viruses, bacteria, and other pathogens) and the means for intervention and prevention. This report is available electronically and in print, in English, French, and Spanish.
Celebrated each year, World Cancer Day is led by UICC and its member organizations, including NCI, with the support of the World Health Organization and key partners.
Learn about NCI’s global cancer research efforts on the Office of International Affairs Web site.
NCI and AACC Partner to Bridge the Gap between Lab and Clinic
NCI, through its Clinical Proteomic Technologies for Cancer (CPTC) initiative, has entered into a memorandum of understanding with the American Association for Clinical Chemistry (AACC) to promote and educate the clinical chemistry community in the area of proteomic standards and technology advances.
This partnership with AACC—an organization that represents professionals engaged in all aspects of clinical chemistry, from performing laboratory tests and analyses to developing new tests and laboratory devices—will provide an effective means for CPTC to educate clinical audiences on the need for and use of standards in multiplex-based proteomic technologies.
NCI established CPTC to address bias and variability in protein-based measurements (analytical, regulatory, and data release policies). This is being achieved through the development of new protein biomarker workflows that are reproducible, quantitative, and reliable. Through education and standardization of laboratory technologies, this partnership has the potential to reduce the amount of time and expenses needed to translate protein biomarker discoveries into clinical use.